Australia - English - Department of Health (Therapeutic Goods Administration)

bard australia pty ltd - 40808 - marker, lesion localization, implantable - disposable applicator with 3 resorbable pga pads, each containing a ribbon shaped titanium wireform with an interwoven pva polymer.pads assist in accurate placement of the marker until they are resorbed in approx 12 weeks.a polyethylene glycol push pellet is present at the end.the wireform is intended for long-term radiographic marking of the biopsy site.the pva polymer is intended for long-term sonographic marking of the biopsy site.applicator fits in a biopsy probe to access the body cavity. an implant used to radiographically and sonographically mark breast tissue during a percutaneous breast biopsy procedure.

Australia - English - Department of Health (Therapeutic Goods Administration)

bard australia pty ltd - 40808 - marker, lesion localization, implantable - disposable applicator with 3 resorbable pga pads, each containing a coil shaped biodur wireform with an interwoven pva polymer.pads assist in accurate placement of the marker until they are resorbed in approx 12 weeks.a polyethylene glycol push pellet is present at the end.the wireform is intended for long-term radiographic marking of the biopsy site.the pva polymer is intended for long-term sonographic marking of the biopsy site.applicator fits in a biopsy probe to access the body cavity. an implant used to radiographically and sonographically mark breast tissue during a percutaneous breast biopsy procedure.

Australia - English - Department of Health (Therapeutic Goods Administration)

device technologies australia pty ltd - 12440 - marker, - markers used to make marks for identification or measuring purposes during ophthalmic surgical procedures.

Israel - English - Ministry of Health

abic marketing ltd, israel - irinotecan hydrochloride trihydrate - concentrate for solution for infusion - irinotecan hydrochloride trihydrate 20 mg/ml - irinotecan - * for the treatment of patients with metastatic colorectal cancer: - in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease. - as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. * for the treatment of patients with small cell lung cancer.* for the treatment of patients with gastric cancer.* irinotecan in combination with leucovorin, oxaliplatin and 5-fluorouracil, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

hologic (australia & new zealand) pty ltd - 40808 - marker, lesion localization, implantable - the securmark biopsy site marker is a sterile, single patient use device comprised of a single, biocompatible titanium marker surrounded by a bioabsorbable suture-like material and a deployment device. the deployment device is a hand-held device that delivers the marker from the distal tip. the deployment device consists of a flexible cannula, handle, flexible push rod, and plunger. the marker is located at the distal end of the deployment device. the securmark biopsy site marker is indicated for the permanent radiographic marking of sites in soft tissue.

Australia - English - Department of Health (Therapeutic Goods Administration)

hologic (australia & new zealand) pty ltd - 40808 - marker, lesion localization, implantable - the securmark biopsy site marker is a sterile, single patient use device comprised of a single, biocompatible titanium marker surrounded by a bioabsorbable suture-like material and a deployment device. the deployment device is a hand-held device that delivers the marker from the distal tip. the deployment device consists of a flexible cannula, handle, flexible push rod, and plunger. the marker is located at the distal end of the deployment device. the securmark biopsy site marker is indicated for the permanent radiographic marking of sites in soft tissue.

Australia - English - Department of Health (Therapeutic Goods Administration)

hologic (australia & new zealand) pty ltd - 40808 - marker, lesion localization, implantable - the securmark biopsy site marker is a sterile, single patient use device comprised of a single, biocompatible titanium marker surrounded by a bioabsorbable suture-like material and a deployment device. the deployment device is a hand-held device that delivers the marker from the distal tip. the deployment device consists of a flexible cannula, handle, flexible push rod, and plunger. the marker is located at the distal end of the deployment device. the securmark biopsy site marker is indicated for the permanent radiographic marking of sites in soft tissue.

Australia - English - Department of Health (Therapeutic Goods Administration)

gamma gurus pty ltd - 40808 - marker, lesion localization, implantable - device is intended to be placed in the body to mark location for a future medical procedure that can be visualized using medical imaging devices. ?coupled markers? and ?suture-type markers? incorporating tissue-absorbable material are not included in this registration.

Australia - English - Department of Health (Therapeutic Goods Administration)

straumann pty ltd - 12440 - marker, - this is a device that is intended to be used to check that the contra angle stop has been aligned with the correct mark (mark on the drill) during a surgical procedure.

Australia - English - Department of Health (Therapeutic Goods Administration)

bard australia pty ltd - 40808 - marker, lesion localization, implantable - radiographic marker intended to mark the location of a breast biopsy procedure.